Summary

A 6-week, open-label trial of a controlled-release formulation of the central nervous system stimulant methylphenidate achieved a dose that, when delivered in the evening, lessens attention deficit hyperactivity disorder symptoms in the morning in children aged 6 to 12 years. Moreover, symptoms are controlled for much of the remaining day.